TVA Medical, Inc., a medical device company developing innovative therapies for end-stage renal disease (ESRD), today announced that its everlinQTM endoAVF System has received NUB (German Neue Untersuchungs und Behandlungsmethoden) Status 1 approval across more than 80 leading hospitals in Germany. (Read More)